Probing the ionotropic activity of glutamate GluD2 receptor in HEK cells with genetically-engineered photopharmacology.
azobenzene
biochemistry
chemical biology
glutamate receptors
ion channels
mouse
neuroscience
optogenetics
photopharmacology
tethered ligands
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
28 10 2020
28 10 2020
Historique:
received:
19
05
2020
accepted:
27
10
2020
pubmed:
29
10
2020
medline:
31
3
2021
entrez:
28
10
2020
Statut:
epublish
Résumé
Glutamate delta (GluD) receptors belong to the ionotropic glutamate receptor family, yet they don't bind glutamate and are considered orphan. Progress in defining the ion channel function of GluDs in neurons has been hindered by a lack of pharmacological tools. Here, we used a chemo-genetic approach to engineer specific and photo-reversible pharmacology in GluD2 receptor. We incorporated a cysteine mutation in the cavity located above the putative ion channel pore, for site-specific conjugation with a photoswitchable pore blocker. In the constitutively open GluD2 Lurcher mutant, current could be rapidly and reversibly decreased with light. We then transposed the cysteine mutation to the native receptor, to demonstrate with high pharmacological specificity that metabotropic glutamate receptor signaling triggers opening of GluD2. Our results assess the functional relevance of GluD2 ion channel and introduce an optogenetic tool that will provide a novel and powerful means for probing GluD2 ionotropic contribution to neuronal physiology. Neurotransmitters are chemicals released by the body that trigger activity in neurons. Receptors on the surface of neurons detect these neurotransmitters, providing a link between the inside and the outside of the cell. Glutamate is one of the major neurotransmitters and is involved in virtually all brain functions. Glutamate binds to two different types of receptors in neurons. Ionotropic receptors have pores known as ion channels, which open when glutamate binds. This is a fast-acting response that allows sodium ions to flow into the neuron, triggering an electrical signal. Metabotropic receptors, on the other hand, trigger a series of events inside the cell that lead to a response. Metabotropic receptors take more time than ionotropic receptors to elicit a response in the cell, but their effects last much longer. One type of receptor, known as the GluD family, is very similar to ionotropic glutamate receptors but does not directly respond to glutamate. Instead, the ion channel of GluD receptors opens after being activated by glutamate metabotropic receptors. GluD receptors are produced throughout the brain and play roles in synapse formation and activity, but the way they work remains unclear. An obstacle to understanding how GluD receptors work is the lack of molecules that can specifically block these receptors’ ion channel activity. Lemoine et al. have developed a tool that enables control of the ion channel in GluD receptors using light. Human cells grown in the lab were genetically modified to produce a version of GluD2 (a member of the GluD family) with a light-sensitive molecule attached. In darkness or under green light, the light-sensitive molecule blocks the channel and prevents ions from passing through. Under violet light, the molecule twists, and ions can flow through the channel. With this control over the GluD2 ion channel activity, Lemoine et al. were able to validate previous research showing that the activation of metabotropic glutamate receptors can trigger GluD2 to open. The next step will be to test this approach in neurons. This will help researchers to understand what role GluD ion channels play in neuron to neuron communication.
Autres résumés
Type: plain-language-summary
(eng)
Neurotransmitters are chemicals released by the body that trigger activity in neurons. Receptors on the surface of neurons detect these neurotransmitters, providing a link between the inside and the outside of the cell. Glutamate is one of the major neurotransmitters and is involved in virtually all brain functions. Glutamate binds to two different types of receptors in neurons. Ionotropic receptors have pores known as ion channels, which open when glutamate binds. This is a fast-acting response that allows sodium ions to flow into the neuron, triggering an electrical signal. Metabotropic receptors, on the other hand, trigger a series of events inside the cell that lead to a response. Metabotropic receptors take more time than ionotropic receptors to elicit a response in the cell, but their effects last much longer. One type of receptor, known as the GluD family, is very similar to ionotropic glutamate receptors but does not directly respond to glutamate. Instead, the ion channel of GluD receptors opens after being activated by glutamate metabotropic receptors. GluD receptors are produced throughout the brain and play roles in synapse formation and activity, but the way they work remains unclear. An obstacle to understanding how GluD receptors work is the lack of molecules that can specifically block these receptors’ ion channel activity. Lemoine et al. have developed a tool that enables control of the ion channel in GluD receptors using light. Human cells grown in the lab were genetically modified to produce a version of GluD2 (a member of the GluD family) with a light-sensitive molecule attached. In darkness or under green light, the light-sensitive molecule blocks the channel and prevents ions from passing through. Under violet light, the molecule twists, and ions can flow through the channel. With this control over the GluD2 ion channel activity, Lemoine et al. were able to validate previous research showing that the activation of metabotropic glutamate receptors can trigger GluD2 to open. The next step will be to test this approach in neurons. This will help researchers to understand what role GluD ion channels play in neuron to neuron communication.
Identifiants
pubmed: 33112237
doi: 10.7554/eLife.59026
pii: 59026
pmc: PMC7679134
doi:
pii:
Substances chimiques
Glutamates
0
Glutamate Dehydrogenase
EC 1.4.1.2
GLUD2 protein, human
EC 1.4.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-16-CE16-0014-01
Pays : International
Organisme : Fondation pour la Recherche Médicale
ID : FRM EQU201903007961
Pays : International
Organisme : Agence Nationale de la Recherche
ID : ANR-11-LABX-0011
Pays : International
Informations de copyright
© 2020, Lemoine et al.
Déclaration de conflit d'intérêts
DL, SM, JT, BL, PF, AT, LT, AM No competing interests declared
Références
Chem Soc Rev. 2011 Aug;40(8):4422-37
pubmed: 21483974
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37
pubmed: 27322406
Elife. 2016 Mar 01;5:
pubmed: 26929991
PLoS One. 2013;8(4):e60785
pubmed: 23560106
J Chem Inf Model. 2013 Aug 26;53(8):1893-904
pubmed: 23379370
FEBS Lett. 1993 Jan 11;315(3):318-22
pubmed: 8422924
J Am Chem Soc. 2018 Jun 20;140(24):7445-7448
pubmed: 29874068
J Struct Biol. 2020 Aug 1;211(2):107546
pubmed: 32512155
Trends Pharmacol Sci. 2019 Sep;40(9):696-710
pubmed: 31400823
Nat Struct Mol Biol. 2020 Jan;27(1):84-91
pubmed: 31925409
Science. 2010 Apr 16;328(5976):363-8
pubmed: 20395510
Curr Opin Pharmacol. 2015 Feb;20:135-43
pubmed: 25573450
Mol Neurobiol. 2008 Apr-Jun;37(2-3):126-41
pubmed: 18521762
Nature. 2017 Sep 7;549(7670):60-65
pubmed: 28737760
Neuroscience. 2001;105(2):443-55
pubmed: 11672610
EMBO Rep. 2014 Jan;15(1):103-9
pubmed: 24357660
Nat Rev Neurosci. 2019 Sep;20(9):514-532
pubmed: 31289380
Biochem Biophys Res Commun. 1993 Dec 30;197(3):1267-76
pubmed: 7506541
PLoS One. 2012;7(3):e32969
pubmed: 22412961
Neuropharmacology. 2017 Mar 15;115:92-99
pubmed: 27276689
Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14116-21
pubmed: 17715062
Hum Mol Genet. 2012 Aug 1;21(15):3513-23
pubmed: 22543975
Trends Neurosci. 2017 Mar;40(3):138-150
pubmed: 28110935
J Neurosci. 2009 Jan 28;29(4):907-17
pubmed: 19176800
PLoS One. 2020 Feb 20;15(2):e0229288
pubmed: 32078638
J Neurosci. 2014 May 28;34(22):7412-24
pubmed: 24872547
Elife. 2018 Sep 04;7:
pubmed: 30176987
J Neurosci. 1997 Jan 15;17(2):834-42
pubmed: 8987804
J Pharmacol Exp Ther. 2003 May;305(2):740-8
pubmed: 12606689
Am J Psychiatry. 2011 Sep;168(9):930-46
pubmed: 21498463
Mol Pharmacol. 2016 Feb;89(2):253-62
pubmed: 26661043
Nat Neurosci. 2000 Apr;3(4):315-22
pubmed: 10725919
Methods Mol Biol. 2016;1408:177-93
pubmed: 26965123
Neuron. 2019 Dec 18;104(6):1081-1094.e7
pubmed: 31704028
Schizophr Res. 2009 Jun;111(1-3):123-30
pubmed: 19346103
Neuron. 2015 Dec 2;88(5):879-891
pubmed: 26606997
J Comp Neurol. 2020 Apr;528(6):1003-1027
pubmed: 31625608
Nature. 1997 Aug 21;388(6644):769-73
pubmed: 9285588
Mol Psychiatry. 2018 Mar;23(3):691-700
pubmed: 28696429
Nucleic Acids Res. 2018 Jul 2;46(W1):W368-W373
pubmed: 29718451
Science. 2016 Jul 15;353(6296):295-9
pubmed: 27418511
Nat Chem Biol. 2006 Jan;2(1):47-52
pubmed: 16408092
Elife. 2020 Apr 01;9:
pubmed: 32234214
J Neurosci. 2000 Aug 15;20(16):5973-80
pubmed: 10934245
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):E5373-E5381
pubmed: 29784783
Brain Struct Funct. 2015 Sep;220(5):2797-815
pubmed: 25001082
J Neurosci. 2008 Feb 6;28(6):1460-8
pubmed: 18256267
Mol Pharmacol. 1996 Mar;49(3):422-9
pubmed: 8643081
Science. 2020 Aug 28;369(6507):
pubmed: 32855309
Mol Psychiatry. 2014 Mar;19(3):294-301
pubmed: 23439483